COSMOS Pharmaceutical Corporation (3349.T)

9053.0035.00 (-0.39%)

COSMOS Pharmaceutical Corporation (3349.T) stock comprehensive Cash Flow Analysis including operating cash flow, investing cash flow, financing cash flow, free cash flow, cash flow from operations, cash flow from investing, cash flow from financing. Compare cash flow against peers/competitors, industry and sector standards.

Low Bankruptcy RiskLow ProfitabilityEfficient OperationsModerate GrowthModerate QualityAdequate Dividend ProfileIndustry Rank: 67.57%Sector Rank: 75.68%

JPX - Healthcare - Medical - Pharmaceuticals | Market Cap: 717.52B | Next Earnings Date: 14 Oct 2025

Day's Range

8935.00 - 9125.00

52-Week Range

6347.00 - 10045.00

Volume

380.0K / 335.9K (Avg.)

P/E Ratio | EPS

23.15 | 391.09

Trending:

3349.T Cash Flow Analysis

Compare against a Competitor

None 3391.T 3141.T 3088.T 2127.T 9843.T

Reveals whether the business's core operations generate sufficient cash to cover expenses, fund growth, and return capital to shareholders. Sustainable free cash flow is often a key indicator of long-term value creation.

Operating Cash Flow per Share

23.81

Decreased from previous period

OCF/share exceeds 1.5x the Medical - Pharmaceuticals median of 0.00. Joel Greenblatt would see if this strong cash generation is sustainable.

Free Cash Flow per Share

3.66

Decreased from previous period

Positive FCF/share while Medical - Pharmaceuticals median is negative. Peter Lynch might see a strong edge over peers.

Capex-to-Operating Cash Flow

84.62%

Increased from previous period

Capex/OCF ratio of 84.62% while the Medical - Pharmaceuticals median is zero. Walter Schloss would confirm if minimal reinvestment is enough for advantage.

Income Quality Ratio (OCF / Net Income)

0.39

Decreased from previous period

Ratio below 0.5x Medical - Pharmaceuticals median of 0.99. Jim Chanos would suspect significant earnings quality problems.

Operating Cash Flow-to-Sales Ratio

1.88%

Decreased from previous period

OCF-to-sales ratio exceeding 1.5x Medical - Pharmaceuticals median of 0.27%. Joel Greenblatt would see a standout ability to convert sales to cash.

Select Chart Metric:

3349.T Cash Flow Analysis

Compare against a Competitor

None 3391.T 3141.T 3088.T 2127.T 9843.T

Operating Cash Flow per Share

23.81

Decreased from previous period

OCF/share exceeds 1.5x the Medical - Pharmaceuticals median of 0.00. Joel Greenblatt would see if this strong cash generation is sustainable.

Free Cash Flow per Share

3.66

Decreased from previous period

Positive FCF/share while Medical - Pharmaceuticals median is negative. Peter Lynch might see a strong edge over peers.

Capex-to-Operating Cash Flow

84.62%

Increased from previous period

Capex/OCF ratio of 84.62% while the Medical - Pharmaceuticals median is zero. Walter Schloss would confirm if minimal reinvestment is enough for advantage.

Income Quality Ratio (OCF / Net Income)

0.39

Decreased from previous period

Ratio below 0.5x Medical - Pharmaceuticals median of 0.99. Jim Chanos would suspect significant earnings quality problems.

Operating Cash Flow-to-Sales Ratio

1.88%

Decreased from previous period

OCF-to-sales ratio exceeding 1.5x Medical - Pharmaceuticals median of 0.27%. Joel Greenblatt would see a standout ability to convert sales to cash.

Select Chart Metric: